Posted by Michael Wonder on 18 Sep 2025
Biogen receives European Commission approval for Zurzuvae (zuranolone), the first and only treatment approved for women with postpartum depression in Europe
17 September 2025 - The EC approval of Zurzuvae is based on the SKYLARK study, which demonstrated rapid relief from depressive symptoms as early as day 3 and sustained through day 45 compared to placebo.
Biogen announced that the European Commission has granted marketing authorisation for Zurzuvae (zuranolone) to treat post-partum depression in adults following childbirth.
